Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Cholangiocarcinoma × Sildenafil Citrate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Erectile Dysfunction 9 Prostatic Neoplasms 8 Rectal Neoplasms 2 Neoplasms 2 Fatigue 2 Brain Neoplasms 2 Waldenstrom Macroglobulinemia 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Solid Tumor 1 Sexuality 1 Sexual Dysfunction, Physiological 1 Sarcoma 1 Radiation Injuries 1 Penile Neoplasms 1 Pancreatic Neoplasms 1 Neurologic Manifestations 1 Mental Fatigue 1 Glioma 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Erectile Dysfunction Following Radical Prostatectomy 1 Cholangiocarcinoma 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Gemcitabine 97 Cisplatin 64 Oxaliplatin 40 pembrolizumab 31 Fluorouracil 30 Capecitabine 30 durvalumab 26 lenvatinib 24 Leucovorin 24 Radiofrequency Ablation 11 Nivolumab 11 Magnetic Resonance Spectroscopy 11 Irinotecan 11 Drug Therapy 11 apatinib 10 Radiotherapy 10 Albumin-Bound Paclitaxel 10 pemigatinib 9 Taxes 9 tislelizumab 8 Specimen Handling 8 Folfox protocol 8 Floxuridine 8 Biopsy 8 Bevacizumab 8 130-nm albumin-bound paclitaxel 8 tremelimumab 7 Liver Transplantation 7 Cholangiopancreatography, Endoscopic Retrograde 7 Carboplatin 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02106871 2017-10-27

PCC

The University of Texas Medical Branch, Galveston

Phase 1 Withdrawn

Gastrointestinal

Fatigue, Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡